advanced breast cancer (metastatic) | entinostat | not classified | versus endocrine therapy alone No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
| T1 vs T0 | | | |
Trial | Treatments | Patients | Method |
---|
ENCORE 301, 2013 | entinostat 5 mg once per week + exemestane 25 mg daily (n=64) vs. exemestane plus placebo (n=66) | Postmenopausal women with ER+ advanced breast cancer progressing on a nonsteroidal aromatase inhibitor | Sample size: 64/66 Primary endpoint: FU duration: |
|